These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1070 related articles for article (PubMed ID: 19009982)
41. The occurrence of reactions and impairments in leprosy: experience in the leprosy control program of three provinces in northeastern Thailand, 1987-1995 [correction of 1978-1995]. I. Overview of the study. Schreuder PA Int J Lepr Other Mycobact Dis; 1998 Jun; 66(2):149-58. PubMed ID: 9728447 [TBL] [Abstract][Full Text] [Related]
42. Relapses among leprosy patients treated with multidrug therapy: experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia; practical difficulties with diagnosing relapses; operational procedures and criteria for diagnosing relapses. Becx-Bleumink M Int J Lepr Other Mycobact Dis; 1992 Sep; 60(3):421-35. PubMed ID: 1474281 [TBL] [Abstract][Full Text] [Related]
43. Are viable Mycobacterium leprae present in lepromatous patients after completion of 12 months' and 24 months' multi-drug therapy? Ebenezer GJ; Daniel S; Norman G; Daniel E; Job CK Indian J Lepr; 2004; 76(3):199-206. PubMed ID: 15835604 [TBL] [Abstract][Full Text] [Related]
44. Incidence of late lepra reaction among multibacillary leprosy patients after MDT. Vijayakumaran P; Manimozhi N; Jesudasan K Int J Lepr Other Mycobact Dis; 1995 Mar; 63(1):18-22. PubMed ID: 7730714 [TBL] [Abstract][Full Text] [Related]
45. OFLOXACIN multicentre trial in MB leprosy FUAM-Manaus and ILSL-Bauru, Brazil. Cunha Mda G; Virmond M; Schettini AP; Cruz RC; Ura S; Ghuidella C; Viana Fdos R; Avelleira JC; Campos AA; Filho B Lepr Rev; 2012 Sep; 83(3):261-8. PubMed ID: 23356027 [TBL] [Abstract][Full Text] [Related]
46. Fixed-duration therapy (FDT) in multibacillary leprosy; efficacy and complications. Vijayakumaran P; Jesudasan K; Manimozhi N Int J Lepr Other Mycobact Dis; 1996 Jun; 64(2):123-7. PubMed ID: 8690969 [TBL] [Abstract][Full Text] [Related]
47. Absence of relapse within 4 years among 34 multibacillary patients with high BIs treated for 2 years with MDT. Jesudasan K; Vijayakumaran P; Manimozhi N; Jeyarajan T; Rao PS Int J Lepr Other Mycobact Dis; 1996 Jun; 64(2):133-5. PubMed ID: 8690971 [TBL] [Abstract][Full Text] [Related]
48. Relapses in leprosy patients after release from dapsone monotherapy; experience in the leprosy control program of the all Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia. Becx-Bleumink M Int J Lepr Other Mycobact Dis; 1992 Jun; 60(2):161-72. PubMed ID: 1522358 [TBL] [Abstract][Full Text] [Related]
49. Comparison of multidrug therapy treatment results between multibacillary leprosy patients in hyperendemic and hypoendemic areas in Gowa Regency, South Sulawesi, Indonesia. Nawi R Southeast Asian J Trop Med Public Health; 2004 Jun; 35(2):340-5. PubMed ID: 15691133 [TBL] [Abstract][Full Text] [Related]
50. Relapse rates following leprosy multidrug therapy. Suite M West Indian Med J; 2000 Sep; 49(3):210-1. PubMed ID: 11076211 [TBL] [Abstract][Full Text] [Related]
51. Comparison of PCR mediated amplification of DNA and the classical methods for detection of Mycobacterium leprae in different types of clinical samples in leprosy patients and contacts. Torres P; Camarena JJ; Gomez JR; Nogueira JM; Gimeno V; Navarro JC; Olmos A Lepr Rev; 2003 Mar; 74(1):18-30. PubMed ID: 12669929 [TBL] [Abstract][Full Text] [Related]
52. Multidrug therapy--the pathway for global leprosy elimination. al-Qubati Y; al-Kubati AS Indian J Lepr; 2000; 72(4):477-90. PubMed ID: 11212482 [TBL] [Abstract][Full Text] [Related]
53. Relapse rates in patients treated with dapsone monotherapy and combinations of dapsone and thiambutosine, thiacetazone, isoniazid and streptomycin in the pre-MDT era. Smith TC; Richardus JH Int J Lepr Other Mycobact Dis; 1994 Sep; 62(3):353-8. PubMed ID: 7525795 [TBL] [Abstract][Full Text] [Related]
54. Gender differences in epidemiological factors associated with treatment completion status of leprosy patients in the most hyperendemic district of Nepal. Kumar RB; Singhasivanon P; Sherchand JB; Mahaisavariya P; Kaewkungwal J; Peerapakorn S; Mahotarn K Southeast Asian J Trop Med Public Health; 2004 Jun; 35(2):334-9. PubMed ID: 15691132 [TBL] [Abstract][Full Text] [Related]
56. Relapse study in smear positive multibacillary (MB) leprosy after 1 year WHO-multi-drug therapy (MDT) in Cebu, Philippines. Maghanoy A; Mallari I; Balagon M; Saunderson P Lepr Rev; 2011 Mar; 82(1):65-9. PubMed ID: 21644473 [TBL] [Abstract][Full Text] [Related]
57. Three years assessment of multidrug therapy in multibacillary leprosy cases. Ganapati R; Revankar CR; Pai RR Indian J Lepr; 1987; 59(1):44-9. PubMed ID: 3611860 [TBL] [Abstract][Full Text] [Related]
58. Clinical, histopathological and bacteriological study of 52 referral MB cases relapsing after MDT. Shetty VP; Wakade AV; Ghate SD; Pai VV; Ganapati RR; Antia NH Lepr Rev; 2005 Sep; 76(3):241-52. PubMed ID: 16248211 [TBL] [Abstract][Full Text] [Related]
59. The efficacy of a four-week, ofloxacin-containing regimen compared with standard WHO-MDT in PB leprosy. Balagon MF; Cellona RV; Abalos RM; Gelber RH; Saunderson PR Lepr Rev; 2010 Mar; 81(1):27-33. PubMed ID: 20496567 [TBL] [Abstract][Full Text] [Related]
60. Changes in the size and number of skin lesions in PB leprosy on treatment and follow-up. Rao PN; Suneetha S; Pratap DV Lepr Rev; 2011 Sep; 82(3):244-52. PubMed ID: 22125932 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]